Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGNOLIA
2022-502737-26-00Phase 2Authorised
- Sponsor
- Gustave Roussy
- Start
- Mar 2023
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of Infracyanine in mouth cancer, oropharyngeal squamous cell carcinoma (OPSCC) and head and neck squamous cell carcinoma (HNSCC), sponsored by Gustave Roussy. Primary endpoint: Sensitivity of real-time near-infrared fluorescence imaging. Planned start Mar 2023; status: authorised.
02
Drugs
Infracyanine
03
Conditions
mouth canceroropharyngeal squamous cell carcinoma (OPSCC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2022-502737-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502737-26-00.